Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

686
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
686
Disorders of Hemostasis01:24

Disorders of Hemostasis

862
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
862
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

7.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.3K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

5.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.6K
Coagulation01:09

Coagulation

6.3K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Survey on current practice in thrombophilia testing: from phenotype to genotype. Communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Diagnosing thrombophilia: the case for genetic or functional testing?

Expert review of molecular diagnostics·2025
Same author

Development of a rapid and fully automated factor VIII inhibitor assay, insensitive to emicizumab, and a lowest level of quantification of 0.2 BU/mL.

Journal of thrombosis and haemostasis : JTH·2024
Same author

Toward harmonized interpretation of anticardiolipin and anti-β2-glycoprotein I antibody detection for diagnosis of antiphospholipid syndrome using defined level intervals and likelihood ratios: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.

Journal of thrombosis and haemostasis : JTH·2024
Same author

Taipan snake venom time has high sensitivity for lupus anticoagulants in non-anticoagulated, triple positive antiphospholipid syndrome patients.

International journal of laboratory hematology·2024
Same author

International Council for Standardization in Haematology Field Study Evaluating Optimal Interpretation Methods for Activated Partial Thromboplastin Time and Prothrombin Time Mixing Studies.

Archives of pathology & laboratory medicine·2023

相关实验视频

Updated: Jun 26, 2025

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

6.8K

血栓友爱查:没有那么简单.

Gary W Moore1,2

  • 1Specialist Haemostasis Laboratory, Cambridge Haemophilia and Thrombophilia Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

Seminars in thrombosis and hemostasis
|May 11, 2024
PubMed
概括

遗传性血栓性并不能保证血栓形成;建议选择性实验室检测. 血栓友爱症的表型分析具有局限性和干扰性,影响诊断的有效性.

科学领域:

  • 血液学 血液学 血液学
  • 临床化学 临床化学

背景情况:

  • 遗传性血栓症是血栓形成的终身风险,但并非所有受影响的人都会患上血栓症.
  • 血栓形成是多因素的,因此不建议不分青红白的血栓形成病例的随意查.
  • 对血栓友爱症的检测应该是有选择的,并告知患者管理层.

研究的目的:

  • 审查常规表型血栓友病试验的性能和局限性.
  • 突出发现抗血,蛋白C和蛋白S等缺陷的挑战.
  • 讨论测试限制对诊断决策和解释的影响.

主要方法:

  • 对血栓友爱症的常规表型试验的审查.
  • 对影响试验性能的局限性和干扰的分析.
  • 对表型和遗传检测方法进行比较,以检测诸如活性蛋白C耐药性等疾病.

主要成果:

  • 对抗血,蛋白C和蛋白S缺乏的表型测定具有局限性,可能无法检测出所有分子特征.
  • 如果仅进行因子V Leiden遗传分析,则检测活性蛋白C耐药性 (APCR) 可能是不完整的.
  • 所有的表型分析都有干扰和局限性,在测试和解释过程中需要仔细考虑.

结论:

更多相关视频

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

13.1K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.0K

相关实验视频

Last Updated: Jun 26, 2025

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

6.8K
Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

13.1K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.0K
  • 对血栓友爱症的选择性实验室检测至关重要,与患者管理目标保持一致.
  • 使用每种缺陷单个试验的血栓友爱症查资料的有效性有限.
  • 了解测试性能和局限性对于准确的诊断和患者护理至关重要.